Back

Treatment of chronic hepatitis C in haemophiliac patients

Abstract number: 1135_256

Husa P., Roznovsky L., Smejkal P., Husova L., Penka M.

Objectives:  

Chronic hepatitis C infection is very common among haemophiliacs in the developed World.

Methods:  

Retrospective evaluation of the treatment results in haemophiliacs with chronic hepatitis C, all infected with genotype 1b. Twelve patients were treated with interferon-alfa monotherapy, 21 patients with interferon-alfa and ribavirin, and 3 patients with pegylated interferon and ribavirin, all for 48 weeks.

Results:  

Sustained virologic response (defined as an undetectable serum HCV RNA level 24 weeks after treatment was completed) was not achieved in any of 12 patients treated with interferon-alfa alone. Combination therapy with interferon-alfa and ribavirin was associated with better results: 4/10 (40%) patients still untreated with interferon-alfa, 2/4 (50%) relapsers, and 2/7 (29%) non-responders to previous interferon-alfa monotherapy achieved sustained virologic responses. Combination therapy with pegylated interferon and ribavirin has been used in 3 patients. Sustained response was achieved in one patient who had relapsed after treatment with interferon-alfa and ribavirin and in 1 of 2 non-responders to this combination therapy. There were no serious adverse events and it was not necessary to reduce dosages or even cease therapy prematurely.

Conclusions:  

The efficacy and tolerability of antiviral treatment in haemophiliacs did not differ from other patients with chronic hepatitis C.

Session Details

Date: 01/08/2007
Time: 00:00-00:00
Session name: XXIst ISTH Congress
Subject:
Location: Oxford, UK
Presentation type:
Back to top